Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer
ClinicalTrials.gov study NCT03920488. IPD Sharing: NO. Countries: 1. Publications: 0.
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast
ClinicalTrials.gov study NCT05422794. IPD Sharing: YES. Countries: 1. Publications: 0.
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04452370. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
ClinicalTrials.gov study NCT05451784. IPD Sharing: NO. Countries: 1. Publications: 0.
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
ClinicalTrials.gov study NCT04348747. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
ClinicalTrials.gov study NCT05067530. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
ClinicalTrials.gov study NCT07372079. IPD Sharing: NO. Countries: 1. Publications: 0.
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
ClinicalTrials.gov study NCT06851299. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
ClinicalTrials.gov study NCT06646263. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
ClinicalTrials.gov study NCT01467310. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
ClinicalTrials.gov study NCT06202313. IPD Sharing: NO. Countries: 1. Publications: 0.
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT04502680. IPD Sharing: NO. Countries: 1. Publications: 0.
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
ClinicalTrials.gov study NCT00777673. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05756166. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
ClinicalTrials.gov study NCT02723877. IPD Sharing: UNDECIDED. Countries: 2. Publications: 0.
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
ClinicalTrials.gov study NCT05954442. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
ClinicalTrials.gov study NCT04045522. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
ClinicalTrials.gov study NCT07208149. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
ClinicalTrials.gov study NCT05999149. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT03644589. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.